Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing

Advances in biotechnology have enabled the development of several high throughput tools, which have led to the establishment of better biomarkers based on genome / exome profiles. Novel biomarkers, such as tumour mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumour infiltrating lymphocytes (TILs) and certain others, are presently being investigated across numerous clinical studies.

I have highlighted below some of the most interesting insights from our study. You can also access additional details here.

---

Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions

---

Several novel biomarkers are presently under investigation for a variety of cancer indications; the initiatives of big pharmaceutical companies are indicative of the growing interest in this domain

---

Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel biomarkers; majority of these tests are intended to facilitate important therapy-related decisions.

---

Multiple tests are currently available for specific diseases indications; next generation sequencing has emerged as a key driver, enabling high throughput results and faster turnaround times

---

Companies involved in this domain are putting in significant efforts to develop efficient tests and differentiate their offerings, from those of other stakeholders, to maintain a competitive edge

---

Till date, close to 200 trials, evaluating the expression of novel biomarkers have been registered across different cancer indications, phases of development and geographical locations

---

The growing research activity in this domain is also evident across published scientific literature; several biomarker-focused studies are evaluating different types of immunotherapies

---

The opportunity is likely to be driven by the applicability of these tests across multiple cancer indications; the market is anticipated to grow as more biomarker based drugs get approved in the coming decade

---

The projected future opportunity is expected to be distributed across different application areas, types of analytical techniques used and various global regions

---

To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com. Alternatively, you can place an Order by filling this Order Form.

---

---